312 related articles for article (PubMed ID: 19366247)
41. A comparative study of the effects of genistein, estradiol and raloxifene on the murine skeletal system.
Sliwiński L; Folwarczna J; Nowińska B; Cegieła U; Pytlik M; Kaczmarczyk-Sedlak I; Trzeciak H; Trzeciak HI
Acta Biochim Pol; 2009; 56(2):261-70. PubMed ID: 19401787
[TBL] [Abstract][Full Text] [Related]
42. The future of the new selective estrogen receptor modulators.
Palacios S
Menopause Int; 2007 Mar; 13(1):27-34. PubMed ID: 17448265
[TBL] [Abstract][Full Text] [Related]
43. Discovery of novel quinoline-based estrogen receptor ligands using peptide interaction profiling.
Hoekstra WJ; Patel HS; Liang X; Blanc JB; Heyer DO; Willson TM; Iannone MA; Kadwell SH; Miller LA; Pearce KH; Simmons CA; Shearin J
J Med Chem; 2005 Mar; 48(6):2243-7. PubMed ID: 15771467
[TBL] [Abstract][Full Text] [Related]
44. Recent advances in the synthesis of raloxifene: a selective estrogen receptor modulator.
Dadiboyena S
Eur J Med Chem; 2012 May; 51():17-34. PubMed ID: 22405286
[TBL] [Abstract][Full Text] [Related]
45. Estrogens and SERMs in coronary heart disease.
Regitz-Zagrosek V; Wintermantel TM; Schubert C
Curr Opin Pharmacol; 2007 Apr; 7(2):130-9. PubMed ID: 17317318
[TBL] [Abstract][Full Text] [Related]
46. Experimental study on the estrogen-like effect of mercuric chloride.
Zhang X; Wang Y; Zhao Y; Chen X
Biometals; 2008 Apr; 21(2):143-50. PubMed ID: 17588195
[TBL] [Abstract][Full Text] [Related]
47. Effects of tamoxifen and estradiol on estrogen binding sites in the urogenital tract: an experimental study in the rabbit.
Iosif CS; al-Hijji J; Samsioe G
Gynecol Endocrinol; 2002 Oct; 16(5):379-83. PubMed ID: 12587532
[TBL] [Abstract][Full Text] [Related]
48. [Selective estrogen receptor modulators: mechanisms of action and their tissue selectivity].
Azuma K; Inoue S
Clin Calcium; 2004 Oct; 14(10):12-26. PubMed ID: 15577127
[TBL] [Abstract][Full Text] [Related]
49. The selective oestrogen receptor modulator, LY362321, is not neuroprotective in a rat model of transient focal ischaemia.
Farr TD; Carswell HV; McCann DJ; Sato M; Bryant HU; Dodge JA; Macrae IM
J Neuroendocrinol; 2008 Mar; 20(3):366-74. PubMed ID: 18208545
[TBL] [Abstract][Full Text] [Related]
50. Estrogen receptor ligands. Part 8: Dihydrobenzoxathiin SERAMs with heteroatom-substituted side chains.
Blizzard TA; DiNinno F; Morgan JD; Wu JY; Chen HY; Kim S; Chan W; Birzin ET; Yang YT; Pai LY; Zhang Z; Hayes EC; DaSilva CA; Tang W; Rohrer SP; Schaeffer JM; Hammond ML
Bioorg Med Chem Lett; 2004 Aug; 14(15):3865-8. PubMed ID: 15225686
[TBL] [Abstract][Full Text] [Related]
51. Single and multiple ascending dose studies of a novel tissue-selective oestrogen receptor modulator, CHF 4227, in healthy postmenopausal women.
Civelli M; Preti AP; Cenacchi V; Rondelli I; Guastalla D; Tarral A; Dostert P; Guillevic Y; Homery MC
Br J Clin Pharmacol; 2007 Sep; 64(3):304-16. PubMed ID: 17367495
[TBL] [Abstract][Full Text] [Related]
52. Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 3: synthesis of cyclopentanone and cyclohexanone intermediates for C-ring modification.
Richardson TI; Dodge JA; Durst GL; Pfeifer LA; Shah J; Wang Y; Durbin JD; Krishnan V; Norman BH
Bioorg Med Chem Lett; 2007 Sep; 17(17):4824-8. PubMed ID: 17614275
[TBL] [Abstract][Full Text] [Related]
53. Investigations on the effects of basic side chains on the hormonal profile of (4R,5S)/(4S,5R)-4,5-bis(4-hydroxyphenyl)-2-imidazolines.
von Rauch M; Busch S; Gust R
J Med Chem; 2005 Jan; 48(2):466-74. PubMed ID: 15658860
[TBL] [Abstract][Full Text] [Related]
54. Estrogen receptor ligands. Part 3: The SAR of dihydrobenzoxathiin SERMs.
Chen HY; Kim S; Wu JY; Birzin ET; Chan W; Yang YT; Dahllund J; DiNinno F; Rohrer SP; Schaeffer JM; Hammond ML
Bioorg Med Chem Lett; 2004 May; 14(10):2551-4. PubMed ID: 15109649
[TBL] [Abstract][Full Text] [Related]
55. [Specific modulators of estrogen action].
Guiochon-Mantel A
Gynecol Obstet Fertil; 2000 Jun; 28(6):429-34. PubMed ID: 10935307
[TBL] [Abstract][Full Text] [Related]
56. Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene.
Overk CR; Peng KW; Asghodom RT; Kastrati I; Lantvit DD; Qin Z; Frasor J; Bolton JL; Thatcher GR
ChemMedChem; 2007 Oct; 2(10):1520-6. PubMed ID: 17654759
[TBL] [Abstract][Full Text] [Related]
57. Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia.
Norman BH; Dodge JA; Richardson TI; Borromeo PS; Lugar CW; Jones SA; Chen K; Wang Y; Durst GL; Barr RJ; Montrose-Rafizadeh C; Osborne HE; Amos RM; Guo S; Boodhoo A; Krishnan V
J Med Chem; 2006 Oct; 49(21):6155-7. PubMed ID: 17034120
[TBL] [Abstract][Full Text] [Related]
58. Synthesis and estrogen receptor binding affinities of 7-hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-ones containing a basic side chain.
Kim YW; Mobley JA; Brueggemeier RW
Bioorg Med Chem Lett; 2003 Apr; 13(8):1475-8. PubMed ID: 12668015
[TBL] [Abstract][Full Text] [Related]
59. Recent advances in estrogen receptor modulators.
Henke BR; Heyer D
Curr Opin Drug Discov Devel; 2005 Jul; 8(4):437-48. PubMed ID: 16022180
[TBL] [Abstract][Full Text] [Related]
60. Ospemifene use in postmenopausal women.
Gennari L; Merlotti D; Valleggi F; Nuti R
Expert Opin Investig Drugs; 2009 Jun; 18(6):839-49. PubMed ID: 19466874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
